Austar Lifesciences (HKG:6118) logged a profit attributable to owners of 25 million yuan for the first half of 2025, up from 5.88 million yuan a year earlier, according to a Tuesday Hong Kong bourse filing.
Earnings per share came in at 0.05 yuan, compared with 0.01 yuan in the prior-year period.
Revenue slipped to 661.9 million yuan from 700.9 million yuan.
The board declared no dividend.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments